Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
about
Proteoglycan form and function: A comprehensive nomenclature of proteoglycansThe Role of NG2 Proteoglycan in GliomaDiversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsetsDynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastomaTheranostic impact of NG2/CSPG4 proteoglycan in cancerEnriched environment reduces glioma growth through immune and non-immune mechanisms in micePD-1, PD-L1, PD-L2 expression in the chordoma microenvironmentEnhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumorsCSPG4: a prototype oncoantigen for translational immunotherapy studies.Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cellsNatural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.The role of microglia and macrophages in glioma maintenance and progressionPrioritization schema for immunotherapy clinical trials in glioblastoma.VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancerCell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumoursTherapeutic potential and challenges of natural killer cells in treatment of solid tumorsChondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.Immune microenvironment of gliomas.NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.The immunological function of GABAergic system.Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies.Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma.Targeting Malignant Brain Tumors with Antibodies.Differential Targeting of Stem Cells and Differentiated Glioblastomas by NK CellsChondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.Immunotherapies for malignant glioma.Trends in Malignant Glioma Monoclonal Antibody Therapy.Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.Fluorine-19 MRI for detection and quantification of immune cell therapy for cancerThe Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human GliomasThe Intracellular Cleavage Product of the NG2 Proteoglycan Modulates Translation and Cell-Cycle Kinetics via Effects on mTORC1/FMRP SignalingLabel-Free Detection of Chondroitin Sulphate Proteoglycan 4 by a Polyaniline/Graphene Nanocomposite Functionalized Impedimetric Immunosensor
P2860
Q21710680-B4E52DD0-A08C-4612-9F7A-F39EEC98009BQ26767702-8504786A-19E9-4C6A-99DE-1D04CA625334Q27334435-A9D86A6C-CA74-4331-86D9-600CD317CE83Q27344690-FCE118BE-E2DB-4986-B9B4-3F06855FBF20Q28085331-797BAF55-5FDF-4EB1-85BA-81666087490DQ30636900-C785B6EF-BF80-495F-8113-D61F3958C1E8Q33275412-E4E8F97E-8E01-4011-82C1-9BCB5A83C7F4Q33728180-BBD89F5D-34C5-4D13-B907-00A89FBE1348Q33763660-646452A4-179A-4C6A-868E-A3D37C93967AQ33862585-34C97148-C006-4C0C-B751-5B45FA2EC757Q35122209-D7146169-3F18-414C-97A7-0AABE939C3BEQ35743681-6FA77418-9F26-49F1-A01E-D80C62C5C85FQ35878535-41E12A88-9AE0-44F2-BDA9-44BE9EA32ACBQ35993525-BD6FB439-ACBC-44D0-923C-6E4C099D7903Q36924298-F059E56E-4D0F-4213-A6E3-2B3BA6099529Q37078999-86EEA5A9-2F26-41CA-938B-AD7B8FC98D2BQ37086056-C93EDDD2-8B14-4B5A-83B2-14E5A9DF9C60Q37282934-D4AB3336-36A9-4B16-AB52-EBD84032C7F4Q38148501-395FEFDD-CC87-48D9-A95A-F55CA7D83AD4Q38478878-2677A2C8-DA71-4EBE-921B-167CC9B0CE57Q38550541-32AA1F11-6A1F-462B-B836-80F677BAF4FFQ38712457-BD3E541E-EE0E-404C-94DF-B277A8D44864Q38941698-89DE2AD0-EEEA-4C48-923A-021F425694F9Q39020795-55E8DCE0-3686-4AE3-B558-275E32CDA8EEQ39196377-97733487-D624-4E9E-B314-68D0B0FF0162Q39242855-E40F7894-5B1E-40D9-BFD6-3285824EC752Q41244801-0029EE83-52AD-4AB9-988D-98E608D1CCEEQ41684107-37CC8D15-6EE7-42DB-B262-F11F4B0F7984Q41924563-C761FBAE-E712-4381-9862-9C0C6DAD51ECQ42267793-5A3DBB2C-51C7-4941-8CB4-113EDE241315Q42281984-19BCC5BC-CBCD-408E-B379-2012241D0CDBQ47555734-9FD3CC4A-76F0-4AA0-86B6-13DC67A42649Q47748770-D194C8CE-3C49-4C58-8479-A4A92BBC979EQ47915209-BCC2388B-F97F-44F2-87FA-5B79A5C5E7C5Q54942652-43F04F8F-A3F9-400D-B1E0-37CB0696AF86Q55456984-6648363C-F683-4012-ADA0-C8CAA4BCFDEAQ57280956-070685BE-BBBD-49AE-8D0E-0B9820810DF2Q58745277-5A5755D4-A331-4AD1-8FD6-0948689BF170Q58797194-C6320140-9F8B-4AC5-A5F7-0BBFCE94E575Q59128614-E1F27952-8D91-427A-95EB-959A9DEEA292
P2860
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
@en
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
@nl
type
label
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
@en
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
@nl
prefLabel
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
@en
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
@nl
P2093
P2860
P356
P1433
P1476
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
@en
P2093
Aurélie Poli
Cecilie Brekke Rygh
Emmet McCormack
François Hentges
Frits Thorsen
Jacques Zimmer
Jesús Planagumà
Kai Ove Skaftnesmo
Martha Chekenya
P2860
P304
P356
10.18632/ONCOTARGET.1291
P407
P577
2013-09-01T00:00:00Z